Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3941264 | 0.96 | MEN1 (0.76) | KMT2AMEN1HDAC4ABL1RIN1 | |
| SCHEMBL8252454 | 0.88 | KMT2A (0.72) | KMT2AMEN1HDAC4ABL1RIN1 | |
| SCHEMBL29188760 | 0.86 | KMT2A (0.70) | KMT2AMEN1HDAC4ABL1RIN1 | |
| SCHEMBL3900270 | 0.86 | KMT2A (0.70) | KMT2AMEN1HDAC4ABL1RIN1 | |
| SCHEMBL5537347 | 0.86 | KMT2A (0.70) | KMT2AMEN1HDAC4ABL1RIN1 | |
| SCHEMBL24052571 | 0.85 | KMT2A (0.51) | KMT2AMEN1NR1H2POLBALDH1A1 | |
| SCHEMBL23709495 | 0.85 | KMT2A (0.69) | KMT2AMEN1HDAC4ABL1RIN1 | |
| SCHEMBL1256025 | 0.85 | KMT2A (0.92) | KMT2AMEN1HDAC4ABL1RIN1 | |
| SCHEMBL3093877 | 0.85 | MEN1 (0.68) | KMT2AMEN1HDAC4ABL1RIN1 | |
| SCHEMBL2365799 | 0.85 | KMT2A (0.68) | KMT2AMEN1HDAC4ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711369-A1 | 1H-[1,2,3]TRIAZOLO[4,5-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| US-12329821-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12252484-B2 | Pyrazolopyridine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2024245406-A1 | 1H-[1,2,3]TRIAZOLO[4,5-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | 成都赛璟生物医药科技有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4310088-A1 | HETEROCYCLIC JAK INHIBITOR | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-20230416242-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230338551-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| CN-113185451-B | Memantine urea derivative, and preparation method and application thereof | 沈阳药科大学 | 2023-09-12 | — | — | CN | disclosed |
| EP-4232059-A1 | DOUBLE DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11730818-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6858641-B2 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040214817-A1 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-28 | — | — | US | disclosed |
| WO-2004046120-A2 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
| EP-1379501-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20030134859-A1 | PPAR-gamma modulator | SANKYO COMPANY, LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| US-20030092756-A1 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-05-15 | — | — | US | disclosed |
| EP-1277729-A1 | PPAR (GAMMA) MODULATORS | Sankyo Company, Limited (JP) | 2003-01-22 | — | — | EP | disclosed |
| WO-2002081445-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416242-A1 | DOUBLE DEGRADERS AND USES THEREOF | DCXR, IDUA, GUSB | KMT2A 1076/4885MEN1 2854/4885HDAC4 1260/4885 |
| US-20030092756-A1 | Substituted indolinones | CDK1, CDK2, CDKL1 | KMT2A 2176/4885MEN1 2916/4885HDAC4 2198/4885 |
| US-12329821-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | KMT2A 1009/4885MEN1 4114/4885HDAC4 2586/4885 |
| US-20030134859-A1 | PPAR-gamma modulator | PPARG, PPARA, PPARD | KMT2A 3291/4885MEN1 4865/4885HDAC4 572/4885 |
| US-12252484-B2 | Pyrazolopyridine compounds for the treatment of autoimmune disease | KCNJ1, KCNJ11, SSB | KMT2A 2248/4885MEN1 437/4885HDAC4 710/4885 |
| US-11730818-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | KMT2A 1009/4885MEN1 4114/4885HDAC4 2586/4885 |
| US-20230338551-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | KMT2A 1009/4885MEN1 4114/4885HDAC4 2586/4885 |
| US-20040214817-A1 | Diaminotriazoles useful as inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K5 | KMT2A 912/4885MEN1 1392/4885HDAC4 1273/4885 |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | CDK1, CDK2, CDK3 | KMT2A 1839/4885MEN1 1664/4885HDAC4 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.